Puru Gaur, MPH, MBA

Director, Commercial Intelligence & Research Services · Prior: Senior Commercial Consultant / Team Lead, Competitive Intelligence

• Lead a team of analysts delivering competitive and market intelligence, forecasting, business intelligence, and market-access decision support for emerging biotech, global pharmaceutical, financial-services, and consulting clients.
• Conduct and oversee oncology competitive-landscape assessments integrating competitor pipelines, clinical trial readouts, regulatory events, mechanisms of action, launch strategy, commercial positioning, market access, and emerging threats to support portfolio, asset, and investment decisions.
• Evaluate platform-technology deals, licensing transactions, partnerships, and proprietary systems that can alter the competitive position or lifecycle value of pharmaceutical assets; assess strategic rationale, economics, technical differentiation, partner selection, and implications for portfolio strategy. Analyze proprietary drug-delivery and formulation technologies — including Halozyme’s ENHANZE® platform — to assess IV-to-subcutaneous conversion, patient experience, lifecycle-management potential, competitive durability, and commercial value.
• Build and review product-level revenue forecasts, epidemiology and patient-flow models, price-volume and uptake scenarios, launch assumptions, and long-range portfolio projections used in commercial planning, asset valuation, lifecycle strategy, and investment decision-making.
• Design and apply algorithmic, machine-learning, and AI-enabled approaches to forecasting, asset prioritization, likelihood-of-approval assessment, competitive monitoring, and custom deal analysis; connect clinical, regulatory, deal, competitive, and commercial data into dashboards, signal-monitoring frameworks, and decision-oriented intelligence products.
• Partner directly with Sales, Account Management, and senior client stakeholders on high-stakes prospect, renewal, and expansion opportunities; shape discovery, use cases, proposals, executive narratives, and live analyses, including SME support that helped preserve and secure a roughly $4M pharmaceutical opportunity.
• Lead prioritization, quality governance, workflow design, cross-brand coordination, and escalations for 200+ monthly intelligence requests while sustaining 93%+ client satisfaction; coach analysts and use AI-assisted performance analytics to inform capacity, quality, and training decisions.

Diversity, Equity & Inclusion and Global Health Research

• Assessed global market-access, reimbursement, epidemiologic, and health-policy environments to inform launch strategy for high-science monoclonal antibody products; conducted stakeholder interviews and translated external evidence into recommendations for global leadership.

Strategic Accounts Consultant

• Engaged PBMs, insurers, group purchasing organizations, and other channel stakeholders to capture real-world perspectives on access, coverage, reimbursement, and market dynamics; produced custom and syndicated insights informing rare-disease strategy and commercialization.

Reimbursement & Policy Insights Analyst

• Managed strategic, multi-million-dollar pharmaceutical client portfolios, including Pfizer Oncology, while serving as client lead for ANI Pharmaceuticals and Indivior; owned senior relationships and coordinated research across reimbursement, payer engagement, pricing, patient access, and specialty commercialization.
• Designed primary and secondary research integrating payer interviews, formulary and utilization-management changes, coverage policy, competitive pricing, reimbursement dynamics, and access barriers into decision-ready recommendations and C-suite-ready presentations.

Health Policy Research

• Analyzed Medicare, Medicaid, 340B, drug affordability, reimbursement, and patient-access policy; translated regulatory and legislative developments into concise, commercially relevant leadership materials for member companies and external stakeholders.

Public Policy & Government Affairs Research

• Supported Alzheimer’s disease launch readiness and broader CNS strategy by translating coverage, reimbursement, access, competitive, and advocacy developments into implications for patients, caregivers, commercial planning, and external engagement.
• Partnered across public affairs, market access, medical, and commercial teams to develop aligned strategic responses to policy change; worked with patient and caregiver advocacy organizations including the Alzheimer’s Association.